Iovance Biotherapeutics Soars 31.48% on Raised FY2026 Revenue Outlook

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has captured the spotlight by soaring an impressive 31.48% to a price of $14.45, as excitement builds around its newly revised fiscal year 2026 revenue outlook. This surge marks a significant milestone, propelling the company to over two-year highs and drawing keen attention from analysts and investors alike. As we […]